A detailed history of Fort Sheridan Advisors LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Fort Sheridan Advisors LLC holds 6,868 shares of BMY stock, worth $396,695. This represents 0.05% of its overall portfolio holdings.

Number of Shares
6,868
Previous 6,007 14.33%
Holding current value
$396,695
Previous $249,000 42.57%
% of portfolio
0.05%
Previous 0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$39.66 - $51.75 $34,147 - $44,556
861 Added 14.33%
6,868 $355,000
Q2 2024

Aug 13, 2024

BUY
$40.25 - $52.99 $65,607 - $86,373
1,630 Added 37.24%
6,007 $249,000
Q1 2024

May 15, 2024

SELL
$47.98 - $54.4 $23,894 - $27,091
-498 Reduced 10.22%
4,377 $237,000
Q3 2023

Nov 08, 2023

SELL
$57.89 - $64.73 $57,890 - $64,730
-1,000 Reduced 17.02%
4,875 $282,000
Q2 2023

Aug 01, 2023

SELL
$63.71 - $70.74 $12,742 - $14,147
-200 Reduced 3.29%
5,875 $375,000
Q1 2023

May 12, 2023

BUY
$65.71 - $74.53 $13,141 - $14,906
200 Added 3.4%
6,075 $421,000
Q4 2022

Feb 15, 2023

SELL
$68.48 - $81.09 $7,943 - $9,406
-116 Reduced 1.94%
5,875 $422,000
Q3 2022

Nov 09, 2022

SELL
$0.13 - $76.84 $21 - $12,832
-167 Reduced 2.71%
5,991 $426,000
Q2 2022

Aug 08, 2022

BUY
$72.62 - $79.98 $75,742 - $83,419
1,043 Added 20.39%
6,158 $474,000
Q1 2022

May 09, 2022

BUY
$61.48 - $73.72 $61 - $73
1 Added 0.02%
5,115 $374,000
Q4 2021

Feb 10, 2022

BUY
$53.63 - $62.52 $16,464 - $19,193
307 Added 6.39%
5,114 $319,000
Q3 2021

Nov 12, 2021

SELL
$59.17 - $69.31 $1,952 - $2,287
-33 Reduced 0.68%
4,807 $284,000
Q2 2021

Aug 17, 2021

SELL
$61.91 - $67.42 $15,477 - $16,855
-250 Reduced 4.91%
4,840 $323,000
Q1 2021

May 17, 2021

BUY
$59.34 - $66.74 $302,040 - $339,706
5,090 New
5,090 $321,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Fort Sheridan Advisors LLC Portfolio

Follow Fort Sheridan Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fort Sheridan Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fort Sheridan Advisors LLC with notifications on news.